184 related articles for article (PubMed ID: 38040221)
1. Methotrexate & rheumatoid arthritis associated atherosclerosis: A narrative review of multidisciplinary approach for risk modification by the international board of experts.
Avagimyan A; Fogacci F; Pogosova N; Kakturskiy L; Jndoyan Z; Faggiano A; Bairamyan T; Agati L; Sattar Y; Mkrchyan L; Avetisyan G; Ginosyan K; Aznauryan A; Sahakyan K; Trofimenko A; Urazova O; Mikhaleva L; Vandysheva R; Kogan E; Demura T; Kc M; Shafie D; Nicola S; Brussino L; Cicero A; Biondi-Zoccai G; Sarrafzadegan N
Curr Probl Cardiol; 2024 Feb; 49(2):102230. PubMed ID: 38040221
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study.
Naranjo A; Sokka T; Descalzo MA; Calvo-Alén J; Hørslev-Petersen K; Luukkainen RK; Combe B; Burmester GR; Devlin J; Ferraccioli G; Morelli A; Hoekstra M; Majdan M; Sadkiewicz S; Belmonte M; Holmqvist AC; Choy E; Tunc R; Dimic A; Bergman M; Toloza S; Pincus T;
Arthritis Res Ther; 2008; 10(2):R30. PubMed ID: 18325087
[TBL] [Abstract][Full Text] [Related]
3. Will antirheumatic treatment improve cardiovascular outcomes in patients with rheumatoid arthritis?
Pieringer H; Pichler M; Pohanka E; Hoppe UC
Curr Pharm Des; 2014; 20(4):486-95. PubMed ID: 23565635
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular risk factors in inflammatory arthritis.
Mirjafari H; Al-Husain A; Bruce IN
Curr Opin Lipidol; 2011 Aug; 22(4):296-301. PubMed ID: 21670670
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular Manifestations in Rheumatoid Arthritis.
Sanghavi N; Ingrassia JP; Korem S; Ash J; Pan S; Wasserman A
Cardiol Rev; 2024 Mar-Apr 01; 32(2):146-152. PubMed ID: 36729119
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular risk in rheumatoid arthritis: how to lower the risk?
van Breukelen-van der Stoep DF; Klop B; van Zeben D; Hazes JM; Castro Cabezas M
Atherosclerosis; 2013 Nov; 231(1):163-72. PubMed ID: 24125429
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular disease in rheumatoid arthritis: Current perspectives on assessing and mitigating risk in clinical practice.
Giles JT
Best Pract Res Clin Rheumatol; 2015; 29(4-5):597-613. PubMed ID: 26697769
[TBL] [Abstract][Full Text] [Related]
8. Atherosclerosis in Rheumatoid Arthritis: Promoters and Opponents.
Carbone F; Bonaventura A; Liberale L; Paolino S; Torre F; Dallegri F; Montecucco F; Cutolo M
Clin Rev Allergy Immunol; 2020 Feb; 58(1):1-14. PubMed ID: 30259381
[TBL] [Abstract][Full Text] [Related]
9. Accelerated Atherosclerosis in Rheumatoid Arthritis: Mechanisms and Treatment.
Reiss AB; Silverman A; Khalfan M; Vernice NA; Kasselman LJ; Carsons SE; De Leon J
Curr Pharm Des; 2019; 25(9):969-986. PubMed ID: 31208307
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular Disease Risk in Older Adults and Elderly Patients with Rheumatoid Arthritis: What Role Can Disease-Modifying Antirheumatic Drugs Play in Cardiovascular Risk Reduction?
Day AL; Singh JA
Drugs Aging; 2019 Jun; 36(6):493-510. PubMed ID: 30953327
[TBL] [Abstract][Full Text] [Related]
11. Rheumatoid arthritis and cardiovascular disease: an update on treatment issues.
Barbhaiya M; Solomon DH
Curr Opin Rheumatol; 2013 May; 25(3):317-24. PubMed ID: 23466960
[TBL] [Abstract][Full Text] [Related]
12. Glucocorticoids and endothelial function in inflammatory diseases: focus on rheumatoid arthritis.
Verhoeven F; Prati C; Maguin-Gaté K; Wendling D; Demougeot C
Arthritis Res Ther; 2016 Nov; 18(1):258. PubMed ID: 27814748
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular events are not associated with MTHFR polymorphisms, but are associated with methotrexate use and traditional risk factors in US veterans with rheumatoid arthritis.
Davis LA; Cannon GW; Pointer LF; Haverhals LM; Wolff RK; Mikuls TR; Reimold AM; Kerr GS; Richards JS; Johnson DS; Valuck R; Prochazka A; Caplan L
J Rheumatol; 2013 Jun; 40(6):809-17. PubMed ID: 23547211
[TBL] [Abstract][Full Text] [Related]
14. Triggers of Cardiovascular Diseases in Rheumatoid Arthritis.
Zhang M; Wang M; Tai Y; Tao J; Zhou W; Han Y; Wei Wei ; Wang Q
Curr Probl Cardiol; 2022 Jun; 47(6):100853. PubMed ID: 34016483
[TBL] [Abstract][Full Text] [Related]
15. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study.
van Halm VP; Nurmohamed MT; Twisk JW; Dijkmans BA; Voskuyl AE
Arthritis Res Ther; 2006; 8(5):R151. PubMed ID: 16984661
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular outcomes of patients with rheumatoid arthritis prescribed disease modifying anti-rheumatic drugs: a review.
Giollo A; Bissell LA; Buch MH
Expert Opin Drug Saf; 2018 Jul; 17(7):697-708. PubMed ID: 29871535
[TBL] [Abstract][Full Text] [Related]
17. Rheumatoid Arthritis Pharmacotherapies: Do They Have Anti-Atherosclerotic Activity?
Giles JT
Curr Rheumatol Rep; 2016 May; 18(5):27. PubMed ID: 27032790
[TBL] [Abstract][Full Text] [Related]
18. Rheumatoid arthritis: cardiovascular manifestations, pathogenesis, and therapy.
Mellana WM; Aronow WS; Palaniswamy C; Khera S
Curr Pharm Des; 2012; 18(11):1450-6. PubMed ID: 22364129
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular Safety of Biologics and JAK Inhibitors in Patients with Rheumatoid Arthritis.
Kang EH; Liao KP; Kim SC
Curr Rheumatol Rep; 2018 May; 20(7):42. PubMed ID: 29846814
[TBL] [Abstract][Full Text] [Related]
20. The management of cardiovascular disease risk in patients with rheumatoid arthritis.
Ahmed O; Krishnamurthy V; Kaba RA; Tahir H
Expert Opin Pharmacother; 2022 Jun; 23(8):947-958. PubMed ID: 35575484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
